Integration addresses critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research
WINSTON-SALEM, N.C., Dec. 22, 2025 /PRNewswire-PRWeb/ -- , a global life science technology company, announces a collaboration with , a leading innovator in automated insulin delivery solutions. This collaboration enables integration of Tandem's Automated Insulin Delivery (AID) systems (Tandem Mobi and t:slim X2) with Clinical ink's GlucoseReadyâ„¢ platform, providing an automated method for capturing AID system data in clinical trials. Type 1 Diabetes participants who opt into a study will have their basal and bolus insulin data securely recorded from their Tandem AID pumps and transmitted directly into the GlucoseReadyâ„¢ platform. This data may remain blinded to participants but available to the sponsor. This advancement complements existing GlucoseReadyâ„¢ capabilities for capturing Continuous Glucose Monitoring (CGM), Blood Glucose Monitoring (BGM) and other digital biomarkers managed per Good Clinical Practice (GCP) principles.
This integration addresses a critical need for accurate, real-time automated insulin delivery data in Type 1 Diabetes clinical research, reducing reliance on manual reporting and improving data integrity. By automating this process, Clinical ink aims to streamline trial workflows, enhance patient experience, and support regulatory compliance.
, MD, CEO of Clinical ink, commented:
"Our partnership with Tandem Diabetes Care represents a significant step forward in the evolution of clinical trials in Type 1 Diabetes. By combining insulin delivery data with CGM and patient-reported outcomes in a single GCP-compliant platform, we enable sponsors to achieve additional transparency and accuracy. This integration strengthens patient engagement and retention, both of which are important in Type 1 Diabetes."
Clinical ink is certified to ISO 13485:2016 for the design, development, and maintenance of our Software as a Medical Device (SaMD) solutions.
, MD, Chief Medical Officer for Tandem Diabetes Care, shared:
"We are pleased to be working with Clinical ink on this initiative. This collaboration sets a new precedent for type 1 diabetes research, and we are proud to see our market-leading advanced insulin delivery systems represented as part of this effort."
More information about automated insulin delivery systems from Tandem Diabetes Care can be found at .
About Clinical ink
is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with eCOA, EDC, connected devices and patient engagement tools (telehealth, eConsent, eRetention), drive the industry standard for precision data capture.
Media Contact
Alissa Dunkin, Clinical ink, 1 3367286819, [email protected],
SOURCE Clinical ink
Share this article